Universal Beteiligungs und Servicegesellschaft mbH Sells 8,089 Shares of Labcorp Holdings Inc. $LH

Universal Beteiligungs und Servicegesellschaft mbH trimmed its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 6.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,352 shares of the medical research company’s stock after selling 8,089 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of Labcorp worth $30,019,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of LH. Harbor Asset Planning Inc. bought a new stake in shares of Labcorp during the second quarter worth $25,000. Financial Gravity Companies Inc. acquired a new position in Labcorp during the 2nd quarter worth about $26,000. Larson Financial Group LLC grew its holdings in Labcorp by 140.4% during the 1st quarter. Larson Financial Group LLC now owns 125 shares of the medical research company’s stock worth $29,000 after acquiring an additional 73 shares during the last quarter. Creative Financial Designs Inc. ADV increased its position in Labcorp by 392.9% in the 2nd quarter. Creative Financial Designs Inc. ADV now owns 138 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 110 shares in the last quarter. Finally, Atlantic Private Wealth LLC acquired a new stake in Labcorp in the 1st quarter valued at about $36,000. Institutional investors own 95.94% of the company’s stock.

Labcorp Trading Down 2.1%

NYSE:LH opened at $261.35 on Tuesday. The company has a current ratio of 1.55, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Labcorp Holdings Inc. has a 1-year low of $209.38 and a 1-year high of $293.72. The firm has a market capitalization of $21.67 billion, a price-to-earnings ratio of 25.67, a PEG ratio of 1.59 and a beta of 0.91. The business’s 50-day moving average price is $273.02 and its two-hundred day moving average price is $263.99.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $4.18 earnings per share for the quarter, beating analysts’ consensus estimates of $4.13 by $0.05. The business had revenue of $3.56 billion for the quarter, compared to the consensus estimate of $3.56 billion. Labcorp had a net margin of 6.21% and a return on equity of 15.85%. Labcorp’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period last year, the company posted $3.50 EPS. Labcorp has set its FY 2025 guidance at 16.150-16.500 EPS. On average, equities analysts expect that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 11th. Investors of record on Wednesday, November 26th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, November 26th. Labcorp’s dividend payout ratio (DPR) is presently 28.29%.

Insider Activity

In other news, Director Richelle P. Parham sold 7,009 shares of Labcorp stock in a transaction dated Friday, October 31st. The stock was sold at an average price of $254.28, for a total transaction of $1,782,248.52. Following the transaction, the director owned 2,469 shares in the company, valued at $627,817.32. The trade was a 73.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Adam H. Schechter sold 5,745 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $262.75, for a total value of $1,509,498.75. Following the completion of the transaction, the chief executive officer owned 87,574 shares of the company’s stock, valued at $23,010,068.50. This represents a 6.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.84% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of Labcorp from $283.00 to $306.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. JPMorgan Chase & Co. upped their price objective on Labcorp from $291.00 to $317.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Evercore ISI increased their price objective on Labcorp from $300.00 to $305.00 and gave the company an “outperform” rating in a research report on Friday, October 3rd. Barclays boosted their target price on Labcorp from $275.00 to $290.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 2nd. Finally, UBS Group cut their price target on Labcorp from $325.00 to $320.00 and set a “buy” rating on the stock in a research note on Wednesday, October 29th. Twelve equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, Labcorp currently has a consensus rating of “Moderate Buy” and an average target price of $297.07.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.